Pieris Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Pieris Pharmaceuticals şirketinin toplam hissedar öz sermayesi $16.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $20.5M ve $4.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$19.36m
Eşitlik	US$16.27m
Toplam yükümlülükler	US$4.25m
Toplam varlıklar	US$20.52m

Son finansal sağlık güncellemeleri

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19

Recent updates

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PIRS 'nin kısa vadeli varlıkları ( $20.5M ) kısa vadeli yükümlülüklerini ( $4.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: PIRS un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PIRS borçsuzdur.

Borcun Azaltılması: PIRS un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PIRS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: PIRS un, serbest nakit akışı her yıl % 5.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Pieris Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

Recent updates

Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)

Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024

Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)

Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction.

New major risk - Share price stability

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pieris Pharmaceuticals, Inc. Announces Executive Changes

New major risk - Financial position

New major risk - Share price stability

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

Consensus revenue estimates fall by 31%

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Price target decreased to US$7.00

Insufficient new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Consensus revenue estimates fall by 48%

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 23%

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Pieris: Early Stage Developer Of Novel Asset Class

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2A Trial of PRS-060/AZD1402

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)

Insufficient new directors

Progress At Pieris Pharmaceuticals

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)

Consensus revenue estimates increase to US$32.5m

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Price target increased to US$8.50

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Consensus revenue estimates fall to US$22.0m

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Price target decreased to US$7.50

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Pieris Pharmaceuticals, Inc. announced that it expects to receive $10.000002 million in funding from AstraZeneca PLC

Pieris Pharmaceuticals, Inc. announced that it has received $13.008671 million in funding

New 90-day low: US$2.41

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

New 90-day high: US$3.19

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Price target raised to US$9.00

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

New 90-day high: US$3.13